NZ337072A - use of an anti-CD40L compounds to inhibit the progression of nephritis, stabilize nephritis or reverse nephritis in a patient with an immune complex disease - Google Patents

use of an anti-CD40L compounds to inhibit the progression of nephritis, stabilize nephritis or reverse nephritis in a patient with an immune complex disease

Info

Publication number
NZ337072A
NZ337072A NZ337072A NZ33707297A NZ337072A NZ 337072 A NZ337072 A NZ 337072A NZ 337072 A NZ337072 A NZ 337072A NZ 33707297 A NZ33707297 A NZ 33707297A NZ 337072 A NZ337072 A NZ 337072A
Authority
NZ
New Zealand
Prior art keywords
nephritis
patient
immune complex
progression
stabilize
Prior art date
Application number
NZ337072A
Other languages
English (en)
Inventor
Susan L Kalled
David W Thomas
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of NZ337072A publication Critical patent/NZ337072A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
NZ337072A 1997-01-10 1997-12-31 use of an anti-CD40L compounds to inhibit the progression of nephritis, stabilize nephritis or reverse nephritis in a patient with an immune complex disease NZ337072A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3467397P 1997-01-10 1997-01-10
PCT/US1997/023482 WO1998030240A1 (en) 1997-01-10 1997-12-31 Treatment of lupus nephritis with anti-cd40l compounds

Publications (1)

Publication Number Publication Date
NZ337072A true NZ337072A (en) 2000-12-22

Family

ID=21877889

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ337072A NZ337072A (en) 1997-01-10 1997-12-31 use of an anti-CD40L compounds to inhibit the progression of nephritis, stabilize nephritis or reverse nephritis in a patient with an immune complex disease

Country Status (19)

Country Link
US (2) US20030031668A1 (enExample)
EP (2) EP1357131A3 (enExample)
JP (1) JP2001508441A (enExample)
KR (2) KR20000070034A (enExample)
CN (2) CN1572325A (enExample)
AU (1) AU5709798A (enExample)
BR (1) BR9714523A (enExample)
CA (1) CA2277222A1 (enExample)
CZ (1) CZ297680B6 (enExample)
EA (2) EA006314B1 (enExample)
EE (1) EE9900273A (enExample)
HU (1) HUP0000833A3 (enExample)
IL (1) IL130784A0 (enExample)
IS (1) IS5100A (enExample)
NO (1) NO993274L (enExample)
NZ (1) NZ337072A (enExample)
PL (1) PL190663B1 (enExample)
TR (7) TR200001249T2 (enExample)
WO (1) WO1998030240A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (en) 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
CN100352497C (zh) * 1998-04-03 2007-12-05 达特茅斯学院理事 应用特异性结合cd40cr(cd40 配体)的抗体抑制体液免疫
IL126681A0 (en) * 1998-10-21 1999-08-17 Opperbas Holding Bv Treatment of trauma-related conditions
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
US7507706B1 (en) 1998-12-14 2009-03-24 Genetics Institute, Llc Cytokine receptor chain
US6171795B1 (en) * 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
US20010055593A1 (en) * 2000-03-14 2001-12-27 Joseph Sypek Use of rapamycin and agents that inhibit B7 activity in immunomodulation
AU8867501A (en) * 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
WO2002022212A2 (en) * 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
MX361174B (es) 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
CN100369932C (zh) * 2005-04-07 2008-02-20 苏州大学 抗人cd154单克隆抗体及其应用
US9044459B2 (en) 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
EP2367849B1 (en) * 2008-12-05 2017-11-01 ALS Therapy Development Institute Method for the treatment of neurodegenerative diseases
US20130310266A1 (en) * 2010-09-03 2013-11-21 Immport Therapeutics, Inc. Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
CA2958578A1 (en) 2014-08-21 2016-02-25 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
AU2016317768A1 (en) * 2015-08-31 2018-02-22 Merck Patent Gmbh Methods for the modulation of LGALS3BP to treat systemic lupus erythematosus
EP3630843A2 (en) 2017-05-24 2020-04-08 ALS Therapy Development Institute Therapeutic anti-cd40 ligand antibodies
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2026092377A1 (zh) * 2024-10-28 2026-05-07 信达生物制药(苏州)有限公司 用cd40l抗体治疗自身免疫病

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
AU1748897A (en) * 1996-01-16 1997-08-11 Biogen, Inc. Therapeutic applications of T-BAM (CD40-L) technology to treat inflammatory kidney diseases
AU2593997A (en) * 1996-03-21 1997-10-10 Trustees Of Columbia University In The City Of New York, The Craf1 (traf-3) isoforms and uses thereof

Also Published As

Publication number Publication date
TR200001249T2 (tr) 2000-11-21
JP2001508441A (ja) 2001-06-26
US20030031668A1 (en) 2003-02-13
EP0948355A1 (en) 1999-10-13
KR20000070034A (ko) 2000-11-25
CN1247472A (zh) 2000-03-15
CN1572325A (zh) 2005-02-02
KR20050089165A (ko) 2005-09-07
TR200001251T2 (tr) 2000-09-21
TR200001250T2 (tr) 2001-03-21
IS5100A (is) 1999-06-30
HUP0000833A2 (en) 2000-07-28
WO1998030240A1 (en) 1998-07-16
PL190663B1 (pl) 2005-12-30
TR200001247T2 (tr) 2002-06-21
PL334495A1 (en) 2000-02-28
EA006314B1 (ru) 2005-10-27
EA200501076A1 (ru) 2006-06-30
EA199900636A1 (ru) 2000-02-28
EE9900273A (et) 2000-02-15
NO993274L (no) 1999-09-10
HUP0000833A3 (en) 2001-09-28
TR199902191T2 (xx) 1999-12-21
BR9714523A (pt) 2000-05-02
US20070190053A1 (en) 2007-08-16
CZ297680B6 (cs) 2007-03-07
NO993274D0 (no) 1999-07-01
TR200001248T2 (tr) 2000-07-21
CZ244499A3 (cs) 1999-10-13
IL130784A0 (en) 2001-01-28
EP1357131A3 (en) 2004-02-11
CA2277222A1 (en) 1998-07-16
AU5709798A (en) 1998-08-03
EP1357131A2 (en) 2003-10-29
TR200001246T2 (tr) 2000-07-21
KR100618081B1 (ko) 2006-08-30

Similar Documents

Publication Publication Date Title
EP0770628A4 (en) Reconstituted human antibody against human interleukin-8
SI1654287T1 (sl) Sestavki polipeptidov ki se vežejo na cd
DK0690851T3 (da) Guanidin-derivater, som er anvendelige til behandling
IL103981A (en) CDw52-SPECIFIC ANTIBODY FOR TREATMENT OF MULTIPLE SCLEROSIS
ZA978865B (en) Reshaped human anti-HM 1.24 antibody.
DK1005870T3 (da) Terapeutisk anvendelse af kimæriske antistoffer mod humant B-lymfocytdifferentieringsantigen til behandling af B-cellelymfom
MXPA02010059A (es) Metodo para administrar un anticuerpo.
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
TR200001250T2 (tr) Ati-CD40L bileşikleri ile lupus nefritis tedavisi
EP0911331A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
NZ337073A (en) use of an anti CD40L compound to treat a patient with an autoimmune disease or chronic immune system disorder
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
DE69718469D1 (de) Verbindungen mit wachtumshormon freisetzenden eigenschaften
WO2001037874A3 (en) Treatment of psoriasis by using an antibody to tnf alpha
EP0339163A3 (en) Monoclonal antibodies specific for hiv and hybridomas for their production
ES8704962A1 (es) Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida.
ATE317263T1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
MY124071A (en) Treatment of viral disease in swine
AU551108B2 (en) Analgesic potentiation of zomepirac with butorphanol
TR199701604T2 (xx) Pirol t�revleri i�in yeni ba�vuru
ES2098304T3 (es) Anticuerpos monoclonales frente a cadenas de hidratos de carbono glucolipidicas.
AU2003230830A8 (en) Treatment of type 1 diabetes before and after expression of predisposition markers
ATE84069T1 (de) Murin-hybridoma lym-2 und diagnostikantikoerper, der dadurch hergestellt ist.
MY106163A (en) Bcrf1 antagonists for treating epstein-barr virus infections.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)